Levetiracetam Tablet
Product Images NDC 55111-248

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 55111-248). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Carton)

Levetiracetam Tablets USP 1000 mg oral tablets carton label from Dr. Reddy's Laboratories Limited. The label shows the product name, strength, dosage form, quantity of 10 tablets (1 blister card with 10 unit doses), and storage instructions. The NDC number 55111-248-79 is displayed along with patient medication guide information for pharmacists.*

FDA Label Image

Container (Container)

Levetiracetam Tablets USP 1000 mg oral tablets in a bottle containing 60 tablets. The label includes NDC 55111-248-60, usage instructions, storage conditions, and specifies it is manufactured by Dr. Reddy's Laboratories Limited. The packaging emphasizes pharmacist attention for patient medication guides and notes controlled room temperature storage.*

FDA Label Image

Figure1 (Figure1)

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The chart shows 7.4% for placebo, 37.1% for 1000 mg/day, and 30.6% for 3000 mg/day of Levetiracetam tablets taken orally.*

FDA Label Image

Figure2 (Figure2)

A bar chart comparing seizure rates among three groups: Placebo (111 patients) with 6.3%, Levetiracetam 1000 mg/day (106 patients) with 20.8%, and Levetiracetam 2000 mg/day (106 patients) with 35.2%. Each bar is labeled with the corresponding percentage and patient count.*

FDA Label Image

Figure3 (Figure3)

A bar graph comparing the number of patients between placebo and Levetiracetam 3000 mg/day groups. The placebo group (N=104) shows a bar representing 14.4%, while the Levetiracetam group (N=180) shows a higher bar representing 39.4%. The y-axis indicates the number of patients, with values up to approximately 4500.*

FDA Label Image

Figure4 (Figure4)

A bar chart comparing the percentage of patients in two groups: Placebo (N=97) and Levetiracetam (N=101). The chart shows a higher percentage for Levetiracetam at 44.6% versus 19.6% for Placebo, with an asterisk indicating statistical significance.*

FDA Label Image

Figure5 (Figure5)

A bar chart comparing the percentage of patients between placebo and levetiracetam treatment groups. The left bar represents placebo with 19.6% of patients, and the right bar represents levetiracetam with 43.1% of patients, indicating a higher percentage for levetiracetam.*

FDA Label Image

Figure6 (Figure6)

A bar chart comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The y-axis represents the percentage of patients, ranging from 0% to 100%. Levetiracetam group shows a bar at 72.2%, while the Placebo group shows a bar at 45.2%, with an asterisk above the Levetiracetam bar.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of Levetiracetam, the active ingredient. The diagram shows the arrangement of atoms including carbon, nitrogen, oxygen, and hydrogen in the molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.